Promis Neurosciences (PMN) Stock
Early stage biotech developing treatments for Alzheimer’s and ALS. Here's the price, business snapshot, and what's worth knowing about Promis Neurosciences in August 2026.
ProMIS Neurosciences Inc (PMN) is a clinical-stage biotechnology company developing targeted immunotherapies for neurodegenerative diseases such as Alzheimer’s and ALS. The company’s approach centres on proprietary antibodies designed to recognise disease‑specific, misfolded protein conformations while avoiding normal forms, aiming to reduce off‑target effects. As a small‑cap, early‑stage issuer with a market capitalisation of roughly $23.7m, ProMIS currently has limited or no product revenues and is dependent on clinical trial progress, partner collaborations and financing to advance programmes. Investment outcomes hinge on binary clinical readouts, regulatory milestones and the company’s ability to manage cash runway, so share price volatility can be high. Investors should treat exposure as speculative, do their own research, consider time horizon and risk tolerance, and note that past performance is not a guide to future returns. This summary is educational only and not personalised investment advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying PROMIS Neurosciences stock, believing it has the potential to rise.
Financial Health
PROMIS Neurosciences is showing strong financial indicators, suggesting good profitability and cash generation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Selective antibody approach
ProMIS targets misfolded, disease‑linked proteins to limit off‑target effects — a technically differentiated strategy, though outcomes depend on clinical validation.
Clinical catalysts to watch
Trial readouts, regulatory updates and partnership deals can be major share‑price drivers; be aware these are binary and can cause sharp moves.
Small‑cap considerations
With a market cap around $23.7m, the stock can be illiquid and volatile; suitable mainly for investors who accept higher risk and potential dilution.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
